Perrigo Among Firms Requesting Delay In Conducting US Nitrosamine Risk Assessments
• By Joanne S. Eglovitch
After OTC and Rx drugs containing ranitidine and other ingredients were linked to nitrosamine, firms marketing drugs in the US have until 1 March to test for impurity risks from the potential carcinogenic associated with chemically synthesized APIs and all approved drugs that contain those APIs.
Explore how consumer health is evolving. On the go.
David Ridley hosts in-depth conversations with industry leaders.
